Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics

Area of Science:

• Biomaterials Science
• Nanotechnology
• Drug Delivery Systems

Background:

• Cancer cells utilize non-essential biomolecules for survival, necessitating targeted therapies.
• Enzyme therapeutics offer specific targeting but face challenges like immune clearance and short half-lives.
• Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) enable controlled release but suffer from burst release and hydrolysis.

Purpose of the Study:

• To develop advanced nanoparticle drug delivery vehicles for therapeutic enzymes.
• To overcome limitations of traditional poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) in drug retention and release.
• To enhance the stability and efficacy of enzyme-based therapeutics through novel encapsulation.

Main Methods:

• Generation of hybrid silica-coated poly(lactic-co-glycolic acid) nanoparticles (SiLGA NPs).
• Characterization of SiLGA NPs for size, Zeta potential, loading efficiency, and content.
• Evaluation of SiLGA NPs' cargo retention and release profile compared to uncoated PLGA NPs.
• Assessment of retained enzymatic activity within SiLGA NPs.

Main Results:

• SiLGA NPs were successfully generated with sub-200 nm diameters and a metastable Zeta potential.
• SiLGA NPs demonstrated high loading efficiency and content for therapeutic enzymes.
• Compared to PLGA NPs, SiLGA NPs exhibited significantly reduced burst release of cargo.
• SiLGA NPs maintained greater enzymatic activity and prolonged cargo retention.

Conclusions:

• SiLGA NPs represent a promising platform for enhanced therapeutic enzyme delivery.
• Encapsulation in SiLGA NPs can mitigate issues of short half-life and frequent administration for enzyme therapeutics.
• This approach holds potential for improving treatment efficacy in diseases requiring enzyme-based therapies, such as cancer.